Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AbbVie's Decnupaz wins FDA approval for blastic plasmacytoid dendritic cell neoplasm, targeting CD123 in Ph1/2
Antibody-drug conjugate, cancer, ADC, blood cancer, BPDCN, CD123 target - Read more

Brazil's Anvisa approves EMS's Ozivy (semaglutide) biosimilar for type 2 diabetes, first generic of Novo Nordisk's Ozempic
Small molecule, metabolic, GLP-1 receptor agonist, type 2 diabetes, semaglutide, biosimilar - Read more

Viridian Therapeutics, WuXi Biologics ink 5-year commercial supply deal for thyroid eye disease drug veligrotug
Manufacturing agreement, ophthalmology, antibody, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

D&D Pharmatech's (zabopegdutide) Ph2 shows fibrosis improvement and MASH resolution in metabolic dysfunction-associated steatohepatitis
Protein therapy, metabolic, GLP-1 receptor agonist, MASH, fibrosis, dual receptor agonist - Read more

GSK, Ionis Pharmaceuticals' (bepirovirsen) achieves Ph3 functional cure in nearly 20% of chronic hepatitis B patients
Antisense oligonucleotide, infectious disease, hepatitis B, functional cure, nucleoside analogue combination - Read more

Kailera Therapeutics’ KAI-4729 shows up to 16% weight loss in Ph1 obesity trial, outpacing rival triple-G agonist data
Small molecule, metabolic, GLP-1 receptor agonist, obesity, triple agonist, weight loss - Read more

Ono Pharmaceutical's ONO-2808 (ONO-2808) Ph2 data show potential in multiple system atrophy, Ph3 planned
Small molecule, neurological, S1P5 receptor agonist, multiple system atrophy, Parkinson's disease - Read more

Kordata Dynamics launches from stealth with AI neural data platform to accelerate clinical trials
AI/digital health, neurological, operational, strategic - Read more

Secretome Therapeutics raises $30M Series A to advance cardiac cell therapies pipeline
Cell therapy, cardiovascular, rare disease, clinical-stage - Read more

Protuoso Biosciences raises $9.5M seed round, advancing hub-and-spoke protein engineering platform
Protein engineering, fusion protein, oncology, autoimmune, cardiometabolic, AI-driven - Read more

NETRIS Pharma secures €7.25M ($8.45M) Horizon Europe grant for Phase 2b head and neck cancer trial
Oncology, clinical-stage, small molecule, head and neck cancer - Read more

Cypher AI raises $2M Seed funding, building AI-native digital infrastructure for life science R&D
AI/ML platform, software platform, data analytics, life sciences R&D - Read more

ClearNote Health raises $52M Series D for cancer early detection expansion
Cancer, early detection, epigenomics, AI/ML platform, liquid biopsy, oncology diagnostics - Read more

CordenPharma acquires AmbioPharm, adding U.S. and China peptide manufacturing sites to expand CDMO capacity
Peptide API, metabolic disease, major transaction, operational - Read more

Biohub releases AI "world model" of protein biology to accelerate therapeutic discovery
Protein design, oncology, AI drug discovery, computational biology - Read more

Verge Genomics rebrands as Verge Labs, pivots to AI drug discovery data after ALS trial failure
Small molecule, neurological, strategic, operational, cost reduction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Johnson & Johnson lays off 56 New Jersey employees amid planned orthopedics business divestiture
MedTech, orthopedics, operational, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here